Edwards Lifesciences Corporation $EW Stock Holdings Cut by Intech Investment Management LLC

Intech Investment Management LLC lessened its position in Edwards Lifesciences Corporation (NYSE:EW) by 50.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 37,913 shares of the medical research company’s stock after selling 39,331 shares during the period. Intech Investment Management LLC’s holdings in Edwards Lifesciences were worth $2,965,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Rosenberg Matthew Hamilton acquired a new position in Edwards Lifesciences during the second quarter worth about $28,000. Quantbot Technologies LP acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $26,000. NewSquare Capital LLC boosted its position in shares of Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 134 shares in the last quarter. SouthState Corp acquired a new position in shares of Edwards Lifesciences in the 1st quarter worth approximately $27,000. Finally, Costello Asset Management INC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $29,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. The trade was a 24.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent research reports. Wells Fargo & Company increased their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research note on Thursday, August 7th. Stifel Nicolaus upped their price target on Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a report on Friday, October 31st. JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Mizuho lifted their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $91.39.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $85.85 on Thursday. The company’s fifty day moving average is $78.52 and its two-hundred day moving average is $77.93. The company has a market cap of $49.82 billion, a P/E ratio of 12.35, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.21. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.